Overview of Seroflo S

Seroflo S is a fixed-dose combination (FDC) respiratory medication delivered as an Inhalation Powder via a Dry Powder Inhaler (DPI), containing two distinct synthetic compounds for chronic airway management. This product is prescribed for patients requiring long-term maintenance treatment.

Property	Description
Active Ingredients	Fluticasone Propionate, Salmeterol Xinafoate
Form	Dry Powder Inhaler (DPI) / Inhalation Powder
Pharmacological Class	Inhaled Corticosteroid / Long-Acting Beta2-Agonist (ICS/LABA) Combination
Common Use	Long-term maintenance therapy for chronic respiratory conditions
Origin	Synthetic

What Type of Respiratory Medicine is Seroflo S?

This medicine belongs to the high-level pharmacological class known as an Inhaled Corticosteroid and Long-Acting Beta2-Agonist (ICS/LABA) combination, a therapeutic approach clinically recognized by major respiratory guidelines for its efficacy in dual-component management. Fluticasone Propionate, a synthetic glucocorticoid, is recognized for its potent anti-inflammatory action.

The composition of this combination product includes the active ingredients Fluticasone Propionate and Salmeterol Xinafoate. Salmeterol is a synthetic long-acting beta2-agonist (LABA), which functions as a bronchodilator. This fixed-ratio formulation is a key differentiating factor, streamlining therapy compared to regimens requiring two separate inhalers. The dry powder dosage form relies on the patient's inhalation effort to deliver the medication, often mixed with a carrier like Lactose Monohydrate, deep into the airways for maximum efficacy.

How Does the Combination Approach Work?

The primary purpose of Seroflo S is to provide long-term maintenance and prophylactic treatment by utilizing a synergistic effect to keep airways calm and open simultaneously. Combination products of this type are specifically intended for foundational, daily support and are not used for immediate, acute symptom relief. This means the medication helps provide consistent, stable support for breathing over time.

The combination strategy provides dual support for chronic conditions: Fluticasone Propionate focuses on airway calming by suppressing the underlying inflammation and swelling within the bronchial tubes, while Salmeterol ensures airway opening by relaxing the constricted muscles around the air passages for an extended period. The fundamental utility of this combination is addressing the two core issues—inflammation and muscle tightening—with one product, offering a consistent and stable management foundation for clear breathing.

What side effects are possible with Seroflo S?

Possible side effects and safety information

The safety profile for this inhaled combination product is defined by adverse reactions classified by frequency and body system, as documented in official regulatory sources. The information focuses strictly on officially listed side effects and mandatory safety statements, not clinical advice or usage instructions.

Frequency-Classified Adverse Reactions

Adverse events are categorized based on clinical trial incidence:

Common (may affect up to 1 in 10 people): Headache, Oral Candidiasis (thrush of the mouth and throat), Nasopharyngitis (cold symptoms), Throat Irritation, Dysphonia (hoarseness), Cough, Bronchitis, Nausea, Vomiting, Dizziness, and Musculoskeletal Pain (including muscle cramps).
Uncommon (may affect up to 1 in 100 people): Tachycardia (fast heart rate), Palpitations, Tremor, Hyperglycemia (increased blood sugar level), Anxiety, Sleep Disturbances, Cataract (eye clouding), and Allergic Skin Rash.
Rare (may affect up to 1 in 1,000 people): Paradoxical Bronchospasm (sudden worsening of breathing immediately after inhalation), Immediate Hypersensitivity Reactions, and Glaucoma (increased pressure in the eye).

Systemic and Population Safety Constraints

Side effects are formally grouped by the body system affected, with specific risks highlighted:

Serious Risks: The official label documents the possibility of Paradoxical Bronchospasm. In patients with Chronic Obstructive Pulmonary Disease (COPD), an increased risk of Pneumonia is noted. Long-term use of the corticosteroid component is associated with potential systemic effects, including Adrenal Suppression and risks to Bone Mineral Density.
Population Notes: Regulatory documents specify that growth velocity should be monitored in pediatric patients. Caution is also advised for use in individuals with severe Hepatic Impairment and those with pre-existing conditions sensitive to beta2-agonists, such as Cardiovascular Disorders and Diabetes Mellitus.
Safety Restriction: Concomitant use with strong CYP3A4 inhibitors is restricted due to the potential for significant increases in systemic corticosteroid exposure and heightened systemic effects.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose manifestations and required emergency actions for Seroflo S (fluticasone propionate/salmeterol), based strictly on government regulatory documents.

Documented Manifestations and Severe Outcomes

Acute overdose is primarily associated with salmeterol (the LABA component), leading to signs of excessive beta-adrenergic stimulation. Chronic or prolonged excessive use is associated with the fluticasone propionate (the ICS component).

Component Risk	Manifestation/Symptom Cluster (Examples)
Salmeterol (Acute)	Cardiovascular: Tachycardia, cardiac arrhythmias, increased blood pressure. Other: Tremor, headache, and transient hypokalemia (low potassium).
Fluticasone (Chronic)	Adrenal suppression, Cushingoid features (Hypercorticism).

Required Emergency Actions

Immediate medical attention is required for any sudden and progressive deterioration in control of asthma or for signs of an acute adrenal crisis, as these are considered potentially life-threatening by regulatory authorities. Acute inhalation of very high doses of the corticosteroid component alone typically does not need emergency action as adrenal function is expected to recover.

Management: There is no specific treatment for the combination overdose. Management is supportive with appropriate monitoring. For salmeterol overdose, cardioselective beta-blocking agents may be considered, but with caution due to the risk of bronchospasm. Potassium replacement should be considered for hypokalemia.

Therapeutic Uses of Seroflo S

Seroflo S is used for the regular maintenance management of chronic respiratory conditions in patients who require ongoing treatment. It is primarily indicated to help manage the symptoms of asthma and Chronic Obstructive Pulmonary Disease (COPD).

The medicine is prescribed for the long-term management of airflow obstruction and to assist in the control of symptoms associated with these conditions. Specific indications include: asthma in adults and adolescents aged 12 years and older, and COPD. The primary benefit is assistance in achieving a more consistent level of symptom control, which may include helping to reduce the frequency of issues such as wheezing, cough, and shortness of breath over time.

Quick Fact: Relief for Breathing Difficulty and Cough

Eligibility and Restrictions for Use

Seroflo S is a combination medicine used for the regular maintenance treatment of certain chronic respiratory conditions. It is specifically indicated for patients who require both an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol) to manage their condition.

Who Can Use Seroflo S?

Seroflo S is typically prescribed for adults and adolescents aged 12 years and older for the management of:

Asthma: When the condition is not adequately controlled with a lower-strength combination product or when the patient is already well-controlled on a mid- or high-dose inhaled corticosteroid and a long-acting beta2-agonist.
Chronic Obstructive Pulmonary Disease (COPD): In patients with severe disease.

Who Should NOT Use Seroflo S?

Seroflo S is contraindicated and should not be used in the following circumstances:

To treat an acute asthma attack or acute bronchospasm. A fast-acting, short-acting bronchodilator (rescue inhaler) must be used for sudden symptoms.
In individuals with a known hypersensitivity or allergy to fluticasone propionate, salmeterol, or any other component of the formulation.
It is generally not recommended for children younger than 12 years of age, as safety and efficacy data are not firmly established for this group.

Use with caution and under close medical supervision is required for patients with pre-existing conditions such as active or quiescent pulmonary tuberculosis, certain cardiovascular disorders, uncorrected hypokalemia (low blood potassium), diabetes, thyroid disorders, or a history of seizure disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Seroflo S, a fixed-dose combination of Fluticasone Propionate and Salmeterol Xinafoate, has officially documented interaction patterns based on the metabolic and pharmacodynamic properties of its two active ingredients.

Contraindicated and Restricted Combinations

Co-administration with other Long-Acting Beta2-Agonists (LABAs) is formally contraindicated by regulatory agencies to prevent an overdose of the bronchodilator component. Furthermore, the use of strong Cytochrome P450 3A4 (CYP3A4) inhibitors, such as Ritonavir or Ketoconazole, is not recommended because this pharmacokinetic interaction significantly increases the systemic exposure of both Fluticasone and Salmeterol. Elevated exposure increases the risk of systemic effects.

Pharmacodynamic and Substance Interactions

Interacting Substance Category	Official Interaction Pattern
Non-Selective Beta-Blockers	Can antagonize the bronchodilating effect of Salmeterol and may produce bronchospasm.
MAOIs and TCAs	These agents may potentiate the cardiovascular effects of the Salmeterol component.
Non-Potassium-Sparing Diuretics	May worsen the known hypokalemic effect associated with beta2-agonists.
Grapefruit Juice	Consumption is noted for potential interaction via CYP3A4 inhibition, which can increase drug exposure.

Population-Specific Cautions

Patients with Hepatic Impairment should be managed with caution because the clearance of both components is predominantly hepatic. Slower clearance can lead to increased systemic drug exposure and potential accumulation.

Mechanism of Action

Seroflo S contains two active compounds that modulate distinct intracellular pathways in the pulmonary tissue. The first component, salmeterol, acts as a selective long-acting beta2-adrenoceptor agonist ( LABA). Salmeterol binds to beta2-adrenergic receptors on the surface of airway smooth muscle cells. This interaction couples with the Gs protein, stimulating adenylyl cyclase activity. The resulting increase in intracellular cyclic adenosine monophosphate (cAMP) activates protein kinase A (PKA). PKA phosphorylation inhibits myosin light chain kinase (MLCK), leading to a reduction in smooth muscle tone.

The second component, fluticasone propionate, functions as a synthetic glucocorticoid receptor agonist. Upon entry into the cell, fluticasone binds with high affinity to the intracellular glucocorticoid receptor (GR/NR3C1). This complex translocates to the nucleus, where it modulates gene transcription. Specifically, the complex binds to glucocorticoid response elements (GREs) to upregulate the expression of anti-inflammatory proteins, and it also acts through transrepression to inhibit the activity of pro-inflammatory transcription factors, such as NF-kappaB. This dual mechanism modifies the synthesis of multiple inflammatory mediators and cellular adhesion molecules, decreasing the localized concentration of inflammatory cells within the airway tissue. The physiological consequences are systemic modulation of bronchial smooth muscle contractility via beta2-agonism and localized, gene-mediated modification of inflammatory signal transduction via glucocorticoid receptor activation.

Dosage and Administration Information

The administration of this fixed-dose combination product is restricted to Oral Inhalation utilizing the specific Dry Powder Inhaler (DPI) device. The medicine is prescribed for long-term maintenance treatment and must be used regularly on a consistent schedule, even when the patient is asymptomatic. It is critical to understand that this product is not intended for the immediate relief of acute breathing difficulties, which requires a separate, short-acting medication.

Dosing and Schedule

The standard regimen requires administration twice daily, with doses scheduled approximately 12 hours apart. The dosage strength—available as Fluticasone Propionate / Salmeterol 100/50 mu g, 250/50 mu g, and 500/50 mu g per inhalation—is selected based on the condition. For Chronic Obstructive Pulmonary Disease (COPD) maintenance, the 250/50 mu g strength is the standard regimen. The total dose administered must not exceed one inhalation of the prescribed strength twice daily.

Procedural Rules

If a dose is missed, it is advised to skip the missed dose and resume the regular schedule; a double dose should never be taken. A crucial procedural requirement is that the patient rinse their mouth with water and spit it out immediately after each dose to manage local residue. The dose strength should be periodically reviewed and titrated to the lowest effective dose that maintains therapeutic control.

Recent Clinical Evidence

Research evidence / Overview of studies for Seroflo S

Evidence for Use in Asthma Maintenance Treatment

The research base includes Randomized Controlled Trials (RCTs), which are comparative studies. These trials often involved the combination product and its single components as study groups. Follow-up durations typically ranged from 12 to 24 weeks.

Studies of this kind were designed to monitor and measure lung function variables and examine patient-reported outcomes describing perceived discomfort and symptoms, including the frequency of nighttime symptoms and the use of rescue inhalers. Research explored outcomes in populations of adults and adolescents (age 12 and older) who had persistent asthma. The trials reported measured differences in these lung function scores between the study groups. Research describes patterns of changes measured during the study period related to symptom scores and the frequency of sudden symptom increases, known as exacerbations. However, results apply only to the populations studied, and findings were sometimes mixed regarding specific outcomes, such as the recorded odds of hospitalization.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research scenarios for this combination in Chronic Obstructive Pulmonary Disease (COPD) were explored in large-scale, long-term Randomized Controlled Trials. These studies were designed to track changes in patients with moderate to severe COPD. Research examined outcomes describing episodic or acute changes, such as the annual frequency of COPD exacerbations, and monitored lung function.

Reports from large trials described patterns observed in the studies related to the annual rate of moderate to severe exacerbations across the groups studied. Studies also reported how patient-reported outcomes describing perceived discomfort and measures of health status evolved in the observed populations. Findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.

Long-Term Research and Extended Follow-up

The research base includes trials with extended follow-up, notably one large study that tracked patients for a duration of three years. This long-term evidence contributes to the broader evidence landscape by allowing researchers to examine outcomes reflecting daily functioning or activity level over sustained periods. However, findings from long-term studies, particularly concerning complex outcomes like all-cause mortality, require careful interpretation, as the predefined statistical significance level was not met in the largest study for this endpoint.

What Is Still Uncertain in the Research Record

The evidence base, while extensive, contains several areas where certainty remains low or where research is ongoing. Follow-up durations were limited in some of the pivotal asthma RCTs, meaning long-term effects are not fully established by those specific trials. There is also limited information available for patients with milder forms of COPD. Furthermore, comparative evidence is lacking from large, head-to-head trials against all other fixed-dose combinations, meaning that findings were mixed regarding some specific comparisons. This includes research gaps related to certain patient subgroups or areas where certainty remains low concerning specific clinical endpoints in long-term follow-up.

Frequently Asked Questions (FAQ)

Common questions about Seroflo S (FAQ)

Q: Is Seroflo S considered a 'controller' or a 'reliever' medication?

A: Official product information describes Seroflo S as a long-term maintenance treatment (or 'controller'). It is specifically not intended for the immediate relief of sudden, acute breathing problems.

Q: Why does Seroflo S contain two different active ingredients?

A: The medicine is a fixed-dose combination that contains an inhaled corticosteroid (to reduce inflammation) and a long-acting beta₂-agonist (to relax airway muscles and keep airways open). The fixed combination is used to address both airway swelling and muscle constriction simultaneously.

Q: How does Seroflo S help to improve breathing over time?

A: According to regulatory sources, the dual components work together: the corticosteroid reduces inflammation and swelling within the lungs, while the long-acting bronchodilator relaxes the constricted airway muscles. This two-part action helps to provide consistent, stable support for clearer breathing over time.

Q: What is the expected duration of effect after using one dose of Seroflo S?

A: The long-acting nature of the beta₂-agonist component suggests effects lasting at least 12 hours, which supports the drug’s typical schedule. The medicine is intended for continuous, maintenance support.

Q: Is it true that long-term use of Seroflo S could weaken the lungs?

A: Regulatory documents address potential systemic effects associated with the corticosteroid component. These include the possibility of a serious effect called Adrenal Suppression and the potential for a reduction in Bone Mineral Density with prolonged use. Patients with these concerns should be monitored by their healthcare provider.

Q: Is Seroflo S an addictive medication?

A: Drug labels and official patient information do not list addiction or physical dependence as a side effect. However, official documentation states treatment should not be stopped abruptly, as this may increase the risk of the condition worsening.

Q: Are there any known effects of Seroflo S on bone health or density?

A: Official information indicates that the long-term use of the inhaled corticosteroid component has been associated with a potential reduction in bone mineral density. This risk is generally linked to systemic corticosteroid exposure.

Q: Can Seroflo S cause shaking or trembling (tremors)?

A: Yes, regulatory documents list tremor and nervousness as uncommon side effects of the medication. These effects are linked to the drug's known safety profile.

Q: Is it safe for a person with a pre-existing heart condition to use Seroflo S?

A: Official safety constraints advise that the medicine must be used with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities. This is due to the potential for the beta₂-agonist component to cause cardiovascular effects.

Q: Are there any general food or beverage restrictions while using Seroflo S?

A: While most foods are not restricted, the consumption of Grapefruit Juice is specifically advised against by regulatory documents. This restriction is due to the potential for Grapefruit Juice to increase the concentration of the medicine in the body.

Q: Are there any specific considerations for older adults using Seroflo S?

A: Regulatory documents state that no dosage adjustment is typically needed for geriatric patients (older adults). Usage is generally consistent with that of the adult population.

Q: Why is Seroflo S not used for sudden, severe breathing attacks?

A: The drug is specifically not indicated for the relief of acute bronchospasm, which is a sudden worsening of breathing. For these sudden, severe symptoms, a fast-acting, short-acting bronchodilator (a rescue inhaler) is required because Seroflo S acts over a longer period.

Q: Is it normal for Seroflo S to seem less effective over time?

A: Official instructions advise patients to seek medical advice if asthma symptoms remain uncontrolled or worsen after starting or while using the medicine. Any potential reduction in effectiveness should be promptly evaluated by a healthcare professional.

Q: Can Seroflo S be used for other lung conditions besides asthma and COPD?

A: According to the official product label, this medicine is only indicated for the long-term maintenance treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD) in the approved populations.

Q: Is the steroid in Seroflo S the same as the 'anabolic steroids' sometimes misused by athletes?

A: No, the inhaled corticosteroid component (Fluticasone Propionate) is a synthetic glucocorticoid. This class of medicine is explicitly not the same as the 'anabolic steroids' that are sometimes misused for muscle-building purposes.

Q: Are there differences in side effects for children compared to adults using Seroflo S?

A: Yes, regulatory documents specify a unique risk for children: growth velocity should be monitored in pediatric patients using this medicine. This is due to the potential for systemic absorption of the corticosteroid component.

Q: What is the information regarding the use of Seroflo S during pregnancy?

A: Official guidelines state that the drug should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Pregnant women with asthma are typically closely monitored by a physician throughout their treatment.

Q: What is the information regarding the use of Seroflo S while breastfeeding?

A: It is officially unknown if the drug is excreted into human breast milk. Official guidance indicates a physician must weigh the risks and benefits to decide whether to discontinue breastfeeding or discontinue the medicine.

Q: Can Seroflo S affect the ability to drive or operate machinery?

A: Official regulatory information states that Seroflo S is not likely to affect a person’s ability to drive or use heavy machinery.

Q: What is a 'spacer device' and when might it be used with Seroflo S?

A: A spacer is a device typically used to help deliver medication from a Metered Dose Inhaler (MDI). Instructions for the Dry Powder Inhaler (DPI) version usually state that it is not intended for use with a spacer device.

Q: What should be done if the Seroflo S device has not been used for two weeks or longer?

A: If the device (MDI version) has not been used for more than four weeks or if it has been dropped, regulatory instructions advise that it should be reprimed before the next use. Repriming is the process of releasing a specific number of sprays into the air.

Q: Is Seroflo S a treatment for nasal polyps?

A: No, the medicine is only indicated for the long-term maintenance treatment of asthma and COPD. It is not prescribed for conditions such as nasal polyps.

Q: Is it safe to use Seroflo S if I have a history of tuberculosis?

A: Official regulatory documents advise that caution is necessary for individuals with a history of active or quiescent pulmonary tuberculosis (TB). Use in this population requires close medical supervision.

Q: What is the importance of the dose counter on the Seroflo S inhaler?

A: The dose counter provides a visual indicator of how many doses remain in the device. Patients are advised to obtain a refill when the counter reaches a low number (as indicated on the specific device) to ensure continuous therapy.

Q: What should be done if a person notices mist coming out of their mouth while inhaling the medicine?

A: The medicine is delivered as a fine powder or mist that the user may or may not feel or taste. Official instructions advise that an extra dose should not be taken, even if the medicine is not sensed after inhalation.

Q: Why is Seroflo S only available with a doctor's prescription?

A: The medication is classified as a Prescription Only Medicine (mathrmRx-only) because its use requires a physician to assess the patient's condition, determine the appropriate dose, and monitor its long-term use for chronic respiratory management.

Q: What is still uncertain in the research record for Seroflo S?

A: The research evidence base contains some areas of low certainty. This includes findings that long-term effects are not fully established by some pivotal trials, and there is limited information available for specific patient groups, such as those with milder forms of COPD.

How should Seroflo S be stored and disposed of?

How to Store and Dispose of Seroflo S?

The official storage and disposal requirements for Seroflo S (Fluticasone Propionate/Salmeterol Dry Powder Inhaler) are designed to maintain the product's stability and ensure environmental safety.

Storage Requirement	Official Condition
Temperature	Store at Controlled Room Temperature (20 C to 25 C), away from direct heat.
Protection	Keep the inhaler in a dry place and do not freeze or wash any part of the device.
Stability Limit	Discard the inhaler 1 month after removal from its original foil pouch, or when the dose counter reads zero, whichever occurs first.
Child Safety	Keep the medication strictly out of the sight and reach of children and pets.

For disposal, unused or expired Seroflo S must not be thrown in household trash or wastewater. It should be discarded via a drug take-back program or following instructions from a healthcare professional, and the empty device must not be punctured or burned.

Seroflo S